Patient Counseling for Finerenone

Sanjay Kalra; Banshi Saboo; Beatrice Anne; Mathew John; Pradip Dalwadi; Shehla Shaikh

doi:10.59793/ijcp.v34i4.598

Authors

Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
Banshi Saboo Dept. of Diabetology, Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India
Beatrice Anne Dept. of Endocrinology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India
Mathew John Dept. of Endocrinology, Providence Endocrine and Diabetes Specialty Centre, Trivandrum, Kerala, India
Pradip Dalwadi Dept. of Endocrinology, Pratham Diabetes and Endocrine Centre, Surat, Gujarat, India
Shehla Shaikh Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.59793/ijcp.v34i4.598

Keywords:

Aldosterone antagonist, chronic kidney disease, diabetic kidney disease, mineralocorticoid receptor antagonist, patient-centered care, person-centered care, type 2 diabetes

Abstract

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist, which is used to retard the progression of chronic kidney disease in persons with type 2 diabetes. This communication describes the various aspects of patient counseling needed to ensure safe and effective usage of the molecule. It utilizes the 5C checklist: Confirmation of clinical indication; Caveats and contraindications; Concerns and checkpoints; Caution and use with concomitant medication; and Constraints and cost, to create a simple, yet comprehensive tool for clinical use.